Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eligard Could Face Two Month Suspension Due To Patent Dispute

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi-Aventis may halt sales of QLT's leuprolide implant until TAP's patent expires in May.

You may also be interested in...

Eligard Temporary Suspension Looms Following Permanent Injunction

QLT is seeking a stay to keep its prostate cancer therapy on the market pending the appeal it plans to file in federal appeals court.

Fast Track Pathway May Be ‘Poor Man’s Breakthrough’ But It Works

Most requests for the FDA’s less-heralded expedited review designation are based on Phase II or earlier data, and have a greater chance of success than requests for breakthrough designation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts